Inovio Pharmaceuticals, Inc. (INO)

NASDAQ: INO · Real-Time Price · USD

1.430

-0.030 (-2.05%)

Nov 13, 2026, 4:00 PM EST - Market closed

Inovio Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	46.96	44.27	65.81	14.31	46.33	71.14
Short-Term Investments	1.4	14.24	28.3	130.98	206.67	330.17
Cash & Short-Term Investments	48.36	58.51	94.11	145.29	253	401.31
Cash Growth	-4.81%	-37.83%	-35.23%	-42.57%	-36.96%	-2.51%
Receivables	-	0	1.2	2.41	11.74	8.03
Prepaid Expenses	3.08	2.61	2.52	5.41	20.51	39.1
Other Current Assets	-	-	-	-	30	-
Total Current Assets	51.44	61.12	97.83	153.11	315.24	448.44
Property, Plant & Equipment	6.78	9.07	11.77	14.45	17.96	29.02
Long-Term Investments	-	2.1	1.61	2.78	2.01	3.91
Goodwill	-	-	-	-	10.51	10.51
Other Intangible Assets	-	-	-	-	2.13	2.63
Other Long-Term Assets	1.92	2.01	1.98	0.61	0.68	1.43
Total Assets	60.14	74.31	113.2	170.95	348.53	495.94

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	13.38	2.62	6.44	4.65	21.08	27.97
Accrued Expenses	1.33	9.16	13.13	18.64	26.42	30.55
Current Portion of Long-Term Debt	-	-	-	16.77	-	-
Current Portion of Leases	2.69	2.82	2.5	2.41	2.8	2.6
Current Unearned Revenue	2.06	-	-	0.11	2.56	4.62
Other Current Liabilities	70.01	29.07	13.26	-	44	-
Total Current Liabilities	89.47	43.67	35.33	42.57	96.87	65.74
Long-Term Debt	-	-	-	-	16.61	14.96
Long-Term Leases	4.59	6.55	9.37	11.03	12.66	15.46
Long-Term Unearned Revenue	-	-	-	-	-	0.06
Long-Term Deferred Tax Liabilities	-	-	-	-	0.03	0.03
Other Long-Term Liabilities	-	-	-	-	-	0.01
Total Liabilities	94.06	50.21	44.69	53.6	126.17	96.27

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.11	0.07	0.04	0.02	0.02	0.22
Additional Paid-In Capital	1,856	1,840	1,799	1,741	1,711	1,610
Retained Earnings	-1,890	-1,815	-1,730	-1,623	-1,488	-1,210
Comprehensive Income & Other	-0.27	-0.64	-0.68	-0.66	-0.7	-0.28
Total Common Equity	-33.92	24.1	68.5	117.35	222.36	399.67
Shareholders' Equity	-33.92	24.1	68.5	117.35	222.36	399.67
Total Liabilities & Equity	60.14	74.31	113.2	170.95	348.53	495.94

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	7.28	9.37	11.87	30.21	32.07	33.02
Net Cash (Debt)	41.08	49.14	82.25	115.08	220.92	368.29
Net Cash Growth	0.73%	-40.25%	-28.53%	-47.91%	-40.01%	-1.16%
Net Cash Per Share	0.53	1.05	3.03	5.19	11.11	21.16
Filing Date Shares Outstanding	187.31	69.09	36.67	23.37	21.68	18.12
Total Common Shares Outstanding	187.31	69	36.1	22.79	21.09	18.12
Working Capital	-38.03	17.45	62.5	110.54	218.37	382.7
Book Value Per Share	-0.18	0.35	1.90	5.15	10.54	22.06
Tangible Book Value	-33.92	24.1	68.5	117.35	209.72	386.53
Tangible Book Value Per Share	-0.18	0.35	1.90	5.15	9.94	21.34
Machinery	-	8.13	8.36	9.9	13.49	20.59
Leasehold Improvements	-	11.82	11.76	15.92	15.8	15.8

SEC Filings: 10-K · 10-Q